<p>Aurinia 制药（AUPH）刚刚提高了 2025 年的收入预期，并分享了季度业绩，显示出与去年相比更强的收入和利润。这些发展本周吸引了投资者的新关注。</p>
<p>查看我们对 Aurinia 制药的最新分析。</p>
<p>在宣布更高的收入目标和强劲的季度利润后，Aurinia 制药的势头不断增强。该股年初至今的股价回报率上升了 76.6%，而一年期的总股东回报率则达到了令人印象深刻的 93.4%。投资者正在关注这些结果，因为它们表明了与早期年份相比，重新焕发的增长潜力和情绪转变。</p>
<p>如果新的收入高点在你的雷达上，你可能还会喜欢发现使用我们精心挑选的医疗股票筛选器的有前景的创新者。查看完整列表：免费查看完整列表。</p>
<p>随着强劲的增长数字和新的指导推高预期，投资者不禁想知道 Aurinia 制药是否仍在以有吸引力的价值交易，还是未来的增长已经反映在今天的价格中。</p>
<h2>最受欢迎的叙述：高估 19.2%</h2>
<p>根据广泛关注的叙述，Aurinia 制药的估计公允价值为 13 美元，显著低于最后的收盘价 15.49 美元，捕捉了投资者的情绪，并引发了关于预期是否过于超前于基本面的质疑。</p>
<blockquote>
<p><em>运营效率的改善，包括 2024 年的战略重组和对成本管理的关注，推动了毛利率的扩张（从中 80% 接近 90%）和运营杠杆的显著增加。这些变化可能会在研发支出增加的情况下提升净利率。（净利率）</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>是什么关键财务举措推动了这一更高的价格？最新的利润率升级和有针对性的增长预测可能是这一大胆估值的关键。查看未来利润如何被规划为这家生物技术公司的下一步。</p>
<p><strong>结果：公允价值为 13 美元（高估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，aritinercept 的开发 setbacks 或对 LUPKYNIS 的依赖增加可能会迅速逆转当前的乐观情绪，并挑战未来的增长假设。</p>
<p>了解 Aurinia 制药叙述的关键风险。</p>
<h2>另一种观点：SWS DCF 模型显示低估</h2>
<p>通过我们的 DCF 模型，Aurinia 制药似乎以远低于其估计公允价值的价格交易。SWS DCF 模型建议每股公允价值为 34.89 美元，这使得当前价格处于深度折扣中。这一巨大差距能否持续，还是市场忽视了什么？</p>
<p>了解 SWS DCF 模型如何得出其公允价值。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/69c169fb-65c3-4c5d-82a9-b2d6d505d821/chart/dcf?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/69c169fb-65c3-4c5d-82a9-b2d6d505d821/chart/dcf"/></p>
<p>截至 2025 年 11 月的 AUPH 折现现金流</p>
<p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看 Aurinia 制药）。我们展示了完整的计算过程。您可以在您的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 894 只基于现金流的低估股票。如果您保存筛选器，我们甚至会在新公司匹配时提醒您——这样您就不会错过潜在机会。</p>
<h2>构建您自己的 Aurinia 制药叙述</h2>
<p>如果您有不同的看法或想要绘制自己的视角，我们的工具可以让您在几分钟内打造个性化的视图。按照您的方式进行。</p>
<p>一个好的起点是我们的分析，强调投资者对 Aurinia 制药的 3 个关键回报的乐观情绪。</p>
<h2>寻找更多聪明的投资想法？</h2>
<p>不要等着别人抢占机会。使用 Simply Wall St 筛选器发现具有真正增长、价值和未来潜力的股票。</p>
<ul>
<li>通过查看这 27 只 AI 便士股票，利用明天的技术优势，这些公司正在人工智能领域开创突破。</li>
<li>通过浏览这些 18 只收益率超过 3% 的股息股票，确保获得有吸引力的回报，这些企业旨在通过高收益股息提供稳定收入。</li>
<li>通过审查这 81 只加密货币和区块链股票，乘坐数字资产的下一个趋势，这是您通往推动加密货币和区块链进步的公司的捷径。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

Aurinia制药

<p>Aurinia 制药（AUPH）已上调其 2025 年收入指引，并报告了更强劲的季度业绩，导致投资者兴趣增加。该股票年初至今的回报率上升了 76.6%，一年回报率为 93.4%。尽管如此，该股票被认为是高估的，公允价值为 13 美元，而最后收盘价为 15.49 美元。然而，DCF 模型表明其被低估，公允价值为 34.89 美元。预计运营效率的提升和战略重组将增强利润率。投资者正在评估未来的增长是否已经被市场定价</p>

<p>Aurinia Pharmaceuticals (AUPH) just lifted its revenue outlook for 2025 and shared quarterly results that showed stronger revenue and profits compared to last year. These developments are drawing fresh attention from investors this week.</p>
<div class="lb-trans"><p>Aurinia 制药（AUPH）刚刚提高了 2025 年的收入预期，并分享了季度业绩，显示出与去年相比更强的收入和利润。这些发展本周吸引了投资者的新关注。</p>
</div><p>See our latest analysis for Aurinia Pharmaceuticals.</p>
<div class="lb-trans"><p>查看我们对 Aurinia 制药的最新分析。</p>
</div><p>After announcing higher revenue targets and robust quarterly profits, Aurinia Pharmaceuticals has seen momentum build. The stock’s year-to-date share price return is up 76.6%, and the one-year total shareholder return stands at an impressive 93.4%. Investors are tuning in as these results signal renewed growth potential and a shift in sentiment compared to earlier years.</p>
<div class="lb-trans"><p>在宣布更高的收入目标和强劲的季度利润后，Aurinia 制药的势头不断增强。该股年初至今的股价回报率上升了 76.6%，而一年期的总股东回报率则达到了令人印象深刻的 93.4%。投资者正在关注这些结果，因为它们表明了与早期年份相比，重新焕发的增长潜力和情绪转变。</p>
</div><p>If new revenue highs are on your radar, you might also enjoy discovering promising innovators using our curated healthcare stock screener. See the full list here: See the full list for free.</p>
<div class="lb-trans"><p>如果新的收入高点在你的雷达上，你可能还会喜欢发现使用我们精心挑选的医疗股票筛选器的有前景的创新者。查看完整列表：免费查看完整列表。</p>
</div><p>With robust growth numbers and new guidance pushing expectations higher, investors are left wondering whether Aurinia Pharmaceuticals is still trading at an attractive value or if future growth is already reflected in today’s price.</p>
<div class="lb-trans"><p>随着强劲的增长数字和新的指导推高预期，投资者不禁想知道 Aurinia 制药是否仍在以有吸引力的价值交易，还是未来的增长已经反映在今天的价格中。</p>
</div><h2>Most Popular Narrative: 19.2% Overvalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：高估 19.2%</h2>
</div><p>According to the widely followed narrative, Aurinia Pharmaceuticals’ estimated fair value of $13 stands notably below the last close price of $15.49, capturing investor sentiment and raising questions about whether expectations have run too far ahead of fundamentals.</p>
<div class="lb-trans"><p>根据广泛关注的叙述，Aurinia 制药的估计公允价值为 13 美元，显著低于最后的收盘价 15.49 美元，捕捉了投资者的情绪，并引发了关于预期是否过于超前于基本面的质疑。</p>
</div><blockquote>
<p><em>Operational efficiency improvements, including a strategic 2024 restructuring and focus on cost management, have driven gross margin expansion (from mid-80s to near 90%) and significant increases in operating leverage. These changes are likely to enhance net margins even as R&amp;D spending increases. (Net margins)</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>运营效率的改善，包括 2024 年的战略重组和对成本管理的关注，推动了毛利率的扩张（从中 80% 接近 90%）和运营杠杆的显著增加。这些变化可能会在研发支出增加的情况下提升净利率。（净利率）</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>What key financial moves are fueling this higher price? The latest margin upgrades and targeted growth projections could be the linchpin for the bold valuation. See how future profits have been mapped out as the next step for this biotech rocket.</p>
<div class="lb-trans"><p>是什么关键财务举措推动了这一更高的价格？最新的利润率升级和有针对性的增长预测可能是这一大胆估值的关键。查看未来利润如何被规划为这家生物技术公司的下一步。</p>
</div><p><strong>Result: Fair Value of $13 (OVERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 13 美元（高估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, setbacks in aritinercept’s development or increased dependence on LUPKYNIS could quickly reverse current optimism and challenge future growth assumptions.</p>
<div class="lb-trans"><p>然而，aritinercept 的开发 setbacks 或对 LUPKYNIS 的依赖增加可能会迅速逆转当前的乐观情绪，并挑战未来的增长假设。</p>
</div><p>Find out about the key risks to this Aurinia Pharmaceuticals narrative.</p>
<div class="lb-trans"><p>了解 Aurinia 制药叙述的关键风险。</p>
</div><h2>Another View: SWS DCF Model Says Undervalued</h2>
<div class="lb-trans"><h2>另一种观点：SWS DCF 模型显示低估</h2>
</div><p>Looking through the lens of our DCF model, Aurinia Pharmaceuticals appears to be trading well below its estimated fair value. The SWS DCF model suggests a fair value of $34.89 per share, which places the current price at a deep discount. Can this big gap persist, or is the market missing something?</p>
<div class="lb-trans"><p>通过我们的 DCF 模型，Aurinia 制药似乎以远低于其估计公允价值的价格交易。SWS DCF 模型建议每股公允价值为 34.89 美元，这使得当前价格处于深度折扣中。这一巨大差距能否持续，还是市场忽视了什么？</p>
</div><p>Look into how the SWS DCF model arrives at its fair value.</p>
<div class="lb-trans"><p>了解 SWS DCF 模型如何得出其公允价值。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/69c169fb-65c3-4c5d-82a9-b2d6d505d821/chart/dcf" alt="" original-src="https://images.simplywall.st/company/69c169fb-65c3-4c5d-82a9-b2d6d505d821/chart/dcf"/></p>
<p>AUPH Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>截至 2025 年 11 月的 AUPH 折现现金流</p>
</div><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Aurinia Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 894 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p>
<div class="lb-trans"><p>Simply Wall St 每天对全球每只股票进行折现现金流（DCF）分析（例如查看 Aurinia 制药）。我们展示了完整的计算过程。您可以在您的观察列表或投资组合中跟踪结果，并在变化时收到提醒，或者使用我们的股票筛选器发现 894 只基于现金流的低估股票。如果您保存筛选器，我们甚至会在新公司匹配时提醒您——这样您就不会错过潜在机会。</p>
</div><h2>Build Your Own Aurinia Pharmaceuticals Narrative</h2>
<div class="lb-trans"><h2>构建您自己的 Aurinia 制药叙述</h2>
</div><p>If you see things differently or want to chart your own perspective, our tools let you craft a personalized view in just a few minutes. Do it your way.</p>
<div class="lb-trans"><p>如果您有不同的看法或想要绘制自己的视角，我们的工具可以让您在几分钟内打造个性化的视图。按照您的方式进行。</p>
</div><p>A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Aurinia Pharmaceuticals.</p>
<div class="lb-trans"><p>一个好的起点是我们的分析，强调投资者对 Aurinia 制药的 3 个关键回报的乐观情绪。</p>
</div><h2>Looking for More Smart Investment Ideas?</h2>
<div class="lb-trans"><h2>寻找更多聪明的投资想法？</h2>
</div><p>Don’t wait while others snap up the opportunities. Use the Simply Wall St Screener to spot stocks with real growth, value, and future potential.</p>
<div class="lb-trans"><p>不要等着别人抢占机会。使用 Simply Wall St 筛选器发现具有真正增长、价值和未来潜力的股票。</p>
</div><ul>
<li>Tap into tomorrow’s technological edge by checking out these 27 AI penny stocks, where companies are pioneering breakthroughs in artificial intelligence.</li>
<li>Secure attractive returns by browsing these 18 dividend stocks with yields &gt; 3%, featuring businesses built to deliver steady income through high-yield dividends.</li>
<li>Ride the next trend in digital assets by reviewing these 81 cryptocurrency and blockchain stocks, your shortcut to firms driving progress in cryptocurrency and blockchain.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过查看这 27 只 AI 便士股票，利用明天的技术优势，这些公司正在人工智能领域开创突破。</li>
<li>通过浏览这些 18 只收益率超过 3% 的股息股票，确保获得有吸引力的回报，这些企业旨在通过高收益股息提供稳定收入。</li>
<li>通过审查这 81 只加密货币和区块链股票，乘坐数字资产的下一个趋势，这是您通往推动加密货币和区块链进步的公司的捷径。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成购买或出售任何股票的推荐，也不考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

Aurinia 制药（纳斯达克股票代码：AUPH）：上调的 2025 年收入指引是否预示着估值的变化？